Literature DB >> 29406241

Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice.

Xiaoli Zhang1, Feng Yang2, Jintao Zou2, Weiru Wu1, Haiming Jing2, Qiang Gou2, Haibo Li2, Jiang Gu2, Quanming Zou2, Jinyong Zhang3.   

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen responsible for a wide range of severe nosocomial and community acquired infections, these infections are major health problems for cystic fibrosis patients and immune-compromised individuals. The emergence of multidrug-resistant isolates highlights the need to develop alternative strategies for treatment of P. aeruginosa infections. Outer membrane vesicles (OMVs) are spherical nanometer-sized proteolipids that are secreted from numerous of pathogenic Gram-negative bacteria, and a number of studies have confirmed the protective efficacy for use of OMVs as candidate vaccines. In this study, OMVs from P. aeruginosa (PA_OMVs) were isolated, formulated with aluminum phosphate adjuvant and used as a vaccine in a mouse model of acute lung infection. The results confirmed that active immunization with PA_OMVs was able to reduce bacterial colonization, cytokine secretion and tissue damage in the lung tissue, thus protecting mice from lethal challenge of P. aeruginosa. Cytokines assay validated that immunization with PA_OMVs was efficient to induce a mixed cellular immune response in mice. Further, high level of specific antibodies was detected in mice immunized with PA_OMVs, and results from opsonophagocytic killing assay and passive immunization suggested that humoral immune response may be critical for PA_OMVs mediated protection. These findings demonstrated that PA_OMVs may be served as a novel candidate vaccine for the prevention of P. aeruginosa infection.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Outer membrane vesicles; Protective efficacy; Pseudomonas aeruginosa; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 29406241     DOI: 10.1016/j.vaccine.2018.01.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Biomimetic Nanotechnology toward Personalized Vaccines.

Authors:  Jiarong Zhou; Ashley V Kroll; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Mater       Date:  2019-06-17       Impact factor: 30.849

2.  Development of IMBs-qPCR detection method for Yersinia enterocolitica based on the foxA gene.

Authors:  Jingxuan Shi; Heng Chi; Aiping Cao; Yinna Song; Min Zhu; Lilin Zhang; Fuzhou Xu; Jinhai Huang
Journal:  Arch Microbiol       Date:  2021-06-26       Impact factor: 2.552

3.  Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model.

Authors:  Mohammad Hadi Fakoor; Seyed Latif Mousavi Gargari; Parviz Owlia; Azar Sabokbar
Journal:  Infect Drug Resist       Date:  2020-06-09       Impact factor: 4.003

4.  Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa.

Authors:  Vandana Solanki; Monalisa Tiwari; Vishvanath Tiwari
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

5.  Proteomic Analysis of Membrane Blebs of Brucella abortus 2308 and RB51 and Their Evaluation as an Acellular Vaccine.

Authors:  Minerva Araiza-Villanueva; Eric Daniel Avila-Calderón; Leopoldo Flores-Romo; Juana Calderón-Amador; Nammalwar Sriranganathan; Hamzeh Al Qublan; Sharon Witonsky; Ma Guadalupe Aguilera-Arreola; María Del Socorro Ruiz-Palma; Enrico A Ruiz; Francisco Suárez-Güemes; Zulema Gómez-Lunar; Araceli Contreras-Rodríguez
Journal:  Front Microbiol       Date:  2019-11-29       Impact factor: 5.640

Review 6.  The Contribution of Membrane Vesicles to Bacterial Pathogenicity in Cystic Fibrosis Infections and Healthcare Associated Pneumonia.

Authors:  Jolien Vitse; Bart Devreese
Journal:  Front Microbiol       Date:  2020-04-09       Impact factor: 5.640

7.  Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC).

Authors:  Rujiu Hu; Jing Li; Yuezhen Zhao; Hua Lin; Liu Liang; Mimi Wang; Haojing Liu; Yuna Min; Yupeng Gao; Mingming Yang
Journal:  Microb Cell Fact       Date:  2020-06-03       Impact factor: 5.328

8.  Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica.

Authors:  Wieslaw Swietnicki; Waldemar Goldeman; Mateusz Psurski; Anna Nasulewicz-Goldeman; Anna Boguszewska-Czubara; Marek Drab; Jordan Sycz; Tomasz M Goszczyński
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

9.  Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection.

Authors:  Peng Li; Xiuran Wang; Xiangwan Sun; Jesse Cimino; Ziqiang Guan; Wei Sun
Journal:  Infect Immun       Date:  2021-07-26       Impact factor: 3.609

10.  Vesicle-Mediated Dendritic Cell Activation in Acinetobacter baumannii Clinical Isolate, which Contributes to Th2 Response.

Authors:  Wei Cai; Dinesh Kumar Kesavan; Jianjun Cheng; Aparna Vasudevan; Huixuan Wang; Jie Wan; Mohamed Hamed Abdelaziz; Zhaoliang Su; Shengjun Wang; Huaxi Xu
Journal:  J Immunol Res       Date:  2019-12-30       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.